公开(公告)号：US20180334495A1

公开(公告)日：2018-11-22

申请号：US15844391

申请日：2017-12-15

Applicant: GENENTECH, INC.

Inventor： Sek Chung FUNG ,  Zhengbin YAO

IPC: C07K16/18 ,  C12N15/113 ,  A61K45/06 ,  A61K38/17 ,  A61K39/395 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K38/00 ,  A61K38/1709 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C12N15/113

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic M retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.

公开(公告)号：US20200291106A1

公开(公告)日：2020-09-17

申请号：US16682773

申请日：2019-11-13

Applicant: Genentech, Inc.

Inventor： Sek Chung FUNG ,  Matthew MOYLE ,  Mason LU ,  Changning YAN ,  Sanjaya SINGH ,  Dan HUANG

IPC: C07K16/24

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

公开(公告)号：US20180251538A1

公开(公告)日：2018-09-06

申请号：US15721570

申请日：2017-09-29

Applicant: GENENTECH, INC.

Inventor： Sek Chung FUNG ,  Matthew MOYLE ,  Mason LU ,  Changning YAN ,  Sanjaya SINGH ,  Dan Huang

IPC: C07K16/24 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/55522 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.